GeoVax Advances Vaccine Programs Amid Global Health Crises Despite Financial Losses

GeoVax Labs reported a net loss of $6.3 million for the third quarter of 2025 while making substantial progress across its vaccine development pipeline, particularly in programs addressing global mpox emergencies and immunocompromised patient needs. The clinical-stage biotechnology company highlighted accelerated development of its GEO-MVA vaccine in response to the World Health Organization's reaffirmation of mpox as a global public health emergency, with Clade I outbreaks continuing across Africa, Europe, and the United States.

David Dodd, GeoVax's Chairman and CEO, emphasized the company's strategic positioning within national health security initiatives. "With continued global mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform," Dodd stated. The company received favorable scientific advice from the European Medicines Agency supporting a streamlined regulatory pathway for GEO-MVA, advancing its goal of becoming a critically important diversified supplier addressing the increasing mpox threat.

The company's multi-antigen approach demonstrated significant promise in COVID-19 vaccination for vulnerable populations. Recent clinical presentations at the 6th ESCMID Conference on Vaccines in Lisbon and iwCLL 2025 Workshop in Krakow validated GEO-CM04S1's performance in immunocompromised patients. The vaccine showed robust T-cell and cross-variant antibody responses in Chronic Lymphocytic Leukemia and hematologic cancer patients, exceeding standard-of-care mRNA vaccines. The CLL trial met its immunogenicity target, prompting discontinuation of the comparator mRNA arm.

GeoVax's oncology program, Gedeptin®, expanded into new solid tumor indications following publication of KEYNOTE-689 Phase 3 results confirming the role of perioperative checkpoint inhibition in head and neck cancer. The company announced plans for a Phase 2 trial evaluating Gedeptin combined with pembrolizumab and fludarabine in first-line, resectable head and neck squamous cell carcinoma, with initiation targeted for the second half of 2026. Simultaneously, preclinical studies are expanding into triple-negative breast and cutaneous cancers in collaboration with Emory University's Winship Cancer Institute.

The company's alignment with U.S. policy priorities positions it favorably within bipartisan calls for onshoring and pandemic preparedness investments. GeoVax's continuous avian cell line manufacturing process supports legislative goals to modernize domestic biomanufacturing and reduce dependency on foreign vaccine suppliers. The company maintains engagements with ASPR, BARDA, CEPI, Africa CDC, WHO, and UNICEF, reinforcing its commitment to biodefense and equitable access.

Financially, research and development expenses decreased to $5.0 million for the quarter, primarily due to discontinued costs associated with termination of the BARDA/RRPV Contract and lower costs for GEO-CM04S1 clinical trials. General and administrative expenses increased to $1.3 million, primarily due to higher personnel costs and investor relations consulting. The company reported cash balances of $5.0 million at September 30, 2025, compared to $5.5 million at December 31, 2024. Further information is included in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission available at https://www.sec.gov.

A new research collaboration with the University of Queensland and UniQuest will evaluate needle-free delivery using Vaxxas' high-density microarray patch platform, targeting improved thermostability, self-administration, and dose-sparing performance. These features are critical for pandemic preparedness and global vaccine equity. The company also sponsored the Dr. David Satcher Global Health Equity Summit to highlight its leadership in equitable vaccine innovation, with additional details available at https://www.geovax.com.